Norrlands universitetssjukhus

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Prostate cancer3 trials
• ALS (motor neurone disease)2 trials
• Atrial fibrillation2 trials
• Colorectal cancer2 trials
• Stroke2 trials
• Childhood cancers1 trial
• Epilepsy1 trial
• Gastric and oesophageal cancer1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Osteoporosis1 trial
• Pancreatic cancer1 trial
• and 2 more

Phase

• Phase 310 trials
• Phase 42 trials
• Phase 2/31 trial

Status

• Recruiting9 trials
• Active, not recruiting5 trials
• Completed1 trial
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Region Skane2 trials
• Umeå University2 trials
• Ab Science1 trial
• AB Science1 trial
• Guri Hagberg1 trial
• and 10 more

Running trials

• Not yet recruiting

  Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD

  NCT07772609· Phase 4· Sahlgrenska University Hospital· Source

  Contact: Anna Ramnemark, MD, PhD

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Guri Hagberg· Source

• Recruiting

  International Care Bundle Evaluation in Cerebral Hemorrhage Research

  NCT06429332· Phase 4· Region Skane· Source

  Contact: Mariann Haapalahti

• Recruiting

  Mediastinal EBUS Cryobiopsy Study In Sweden

  NCT06347939· Region Skane· Source

  Contact: Annelie Behndig, MD, PhD

• Recruiting

  EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE

  NCT07253701· Karolinska Institutet· Source

  Contact: Måns Berglund, MD

• Enrolling by invitation

  Nurse-led Proactive Telephone Follow-up With Patients After Completion of Primary Cancer Treatment

  NCT06223022· Umeå University· Source

• Recruiting

  Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

  NCT05448547· Phase 3· Sven Löffeler· Source

  Contact: Hani Adamo, MD

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Active, not recruiting

  A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  NCT05071300· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Recruiting

  SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

  2024-510578-25-00· Phase 3· The University Of Birmingham· Source

• Recruiting

  Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

  NCT03127267· Phase 3· AB Science· Source

  Contact: Clinical Study Coordinator

• Recruiting

  Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

  NCT04460352· Phase 3· Karolinska University Hospital· Source

  Contact: Birgitta Orrvik Olsson, RN

• Active, not recruiting

  Person Centered Nurse Led Atrial Fibrillation Care

  NCT04609202· Umeå University· Source

• Active, not recruiting

  Nordic Pancreatic Cancer Trial (NorPACT) - 1

  NCT02919787· Phase 2/3· Oslo University Hospital· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source

• Active, not recruiting

  Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

  NCT01558921· Phase 3· University Medical Center Groningen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Stroke2 recruiting
• ALS (motor neurone disease)1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Epilepsy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting
• Osteoporosis1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoidosis1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Suspended

  A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

  2024-516671-33-00· Phase 3· Ab Science· Source